We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 02, 2021

Zanubrutinib in Patients With Relapsed/Refractory Waldenström Macroglobulinemia

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients With Relapsed/Refractory Waldenström Macroglobulinemia
Clin. Cancer Res 2021 Jul 12;[EPub Ahead of Print], G An, D Zhou, S Cheng, KS Zhou, J Li, J Zhou, L Xie, J Jin, LY Zhong, L Yan, H Guo, C Du, J Zhong, Y Yu, B Wu, L Qiu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading